TABLE 2.

Demographics and disease characteristics of patients with probable and possible CAPA^a

Case	ECMM/ISHAM CAPA classification	EORTC/MSG host factors	Age, sex	Underlying disease	Mechanical ventilation	Systemic corticosteroids for COVID	Tocilizumab for COVID	Mycological evidence for CAPA	Antifungal therapy	Patient alive at ICU discharge
Patient 1	Probable	None	63, m	Hypertension, coronary heart disease	No	Yes	No	BAL, GM, PCR	Isavu	No
Patient 2	Probable	None	60, m	Hypertension	Yes	Yes	No	BAL, GM, PCR, culture, LFD, serum GM	Isavu	Yes
Patient 3	Probable	None	65, m	Hypertension	Yes	No	No	Serum GM, tracheal aspiration, LFD+	Isavu	No
Patient 4	Probable	None	58, m	JAK-2-positive essential thrombocythemia	Yes	Yes	No	NBL, culture, GM, PCR, serum GM	Vori	No
Patient 5	Probable	None	58, m	Diabetes mellitus type 2, hypertension	Yes	Yes	Yes	BAL GM, serum GM	Vori	No
Patient 6	Probable	None	53, f	Malignant neoplasm of rectum, stage 3 cervical cancer, bronchial asthma	Yes	Yes	No	BAL GM, NBL culture	L-AmB	No
Patient 7	Possible	None	52, m	None	Yes	Yes	Yes	NBL GM	Vori	Yes
Patient 8	Possible	None	72, f	Hypertension	Yes	No	No	NBL GM	Vori	Yes

^aBAL, bronchoalveolar lavage; CAPA, COVID-19-associated pulmonary aspergillosis; ECMM, European Confederation for Medical Mycology; EORTC, European Organization for Research and Treatment in Cancer; f, female; GM, galactomannan; ICU, intensive care unit; Isavu, isavuconoazle; ISHAM, International Society for Human and Animal Mycoses; L-AmB, liposomal amphotericin-B; LFD, lateral flow device; m, male; MSG, Mycoses Study Group; NBL, nonbronchoscopic lavage; SOT, solid organ transplantation; TB, tuberculosis; Vori, voriconazole.